Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection (DME, CRTH258B1401)
ClinicalTrials.gov Identifier: NCT05526729
Novartis Reference Number: CRTH258B1401
Last Update: Mar 10, 2023
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
This is a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.
Patients must provide written consent to cooperate in this study before the start of treatment with Beovu
Patients using Beovu for the first time for the following indication • Indication: diabetic macular edema
1. Patients with a history of treatment with a drug containing the same ingredient (brolucizumab) as Beovu